AIM
PBYI icon

Acrospire Investment Management’s Puma Biotechnology PBYI Stock Holding History

Acrospire Investment Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-54
Closed -$5K – 1028
2017
Q2 		$5K Buy
+54
New +$3.02K ﹤0.01% 1961

Other funds holding PBYI

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acrospire Investment Management's PBYI Position: Q3 2017 in Review

Acrospire Investment Management sold out of Puma Biotechnology (PBYI) in Q3 2017, closing a stake of 54 shares — an estimated $5K sold.

Acrospire Investment Management first reported a position in PBYI in Q2 2017 and held it in 1 quarter. The position peaked at $5K in Q2 2017. 171 funds tracked by Wall St. Rank hold PBYI as of Q3 2017.

  • Acrospire Investment Management reported no remaining Puma Biotechnology position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 54 Puma Biotechnology shares in Q3 2017, an estimated $5K.
  • Acrospire Investment Management first reported a position in Puma Biotechnology in Q2 2017 and held it in 1 quarter.
  • Acrospire Investment Management's Puma Biotechnology position peaked at $5K in Q2 2017.
  • 171 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.